REFERENCES

1. Wang T, Han Z, Yang Y, et al. Polygenic risk score for Alzheimer’s Disease is associated with ch4 volume in normal subjects. Front. Genet. 2019;10:519.

2. 2023 Alzheimer’s disease facts and figures. Alzheimers Dement. 2023;19:1598-695.

3. Seto M, Weiner RL, Dumitrescu L, Hohman TJ. Protective genes and pathways in Alzheimer’s disease: moving towards precision interventions. Mol Neurodegener. 2021;16:29.

4. Lambert J, Grenier-Boley B, Chouraki V, et al. Implication of the immune system in Alzheimer’s disease: evidence from genome-wide pathway analysis. J Alzheimers Dis. 2010;20:1107-18.

5. Reitz C, Pericak-Vance MA, Foroud T, Mayeux R. A global view of the genetic basis of Alzheimer disease. Nat Rev Neurol. 2023;19:261-77.

6. Pericak-Vance MA, Bebout JL, Gaskell PC, Jr, et al. Am J Hum Genet. 1991;48:1034-50.

7. Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science. 1993;261:921-3.

8. Lambert J, Ibrahim-Verbaas CA, Harold D, et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer’s disease. Nat Genet. 2013;45:1452-8.

9. Wightman DP, Jansen IE, Savage JE, et al. ; 23andMe Research Team. A genome-wide association study with 1,126,563 individuals identifies new risk loci for Alzheimer’s disease. Nat Genet. 2021;53:1276-82.

10. Kunkle BW, Grenier-Boley B, Sims R, et al. Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing. Nat Genet. 2019;51:414-30.

11. Bellenguez C, Küçükali F, Jansen IE, et al. New insights into the genetic etiology of Alzheimer’s disease and related dementias. Nat Genet. 2022;54:412-36.

12. Grangeon L, Lange KS, Waliszewska-Prosół M, et al. ; European Headache Federation School of Advanced Studies (EHF-SAS). Genetics of migraine: where are we now? J Headache Pain. 2023;24:12.

13. Khan J, Asoom LIA, Sunni AA, et al. Genetics, pathophysiology, diagnosis, treatment, management, and prevention of migraine. Biomed Pharmacother. 2021;139:111557.

14. Steiner TJ, Stovner LJ. Global epidemiology of migraine and its implications for public health and health policy. Nat Rev Neurol. 2023;19:109-17.

15. Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38:1-211.

16. Hautakangas H, Winsvold BS, Ruotsalainen SE, et al. Genome-wide analysis of 102,084 migraine cases identifies 123 risk loci and subtype-specific risk alleles. Nat Genet. 2022;54:152-60.

17. Anttila V, Stefansson H, Kallela M, et al. ; International Headache Genetics Consortium. Genome-wide association study of migraine implicates a common susceptibility variant on 8q22.1. Nat Genet. 2010;42:869-73.

18. Chasman DI, Schürks M, Anttila V, et al. Genome-wide association study reveals three susceptibility loci for common migraine in the general population. Nat Genet. 2011;43:695-8.

19. Freilinger T, Anttila V, de Vries B, et al. ; International Headache Genetics Consortium. Genome-wide association analysis identifies susceptibility loci for migraine without aura. Nat Genet. 2012;44:777-82.

20. Gormley P, Anttila V, Winsvold BS, et al. ; International Headache Genetics Consortium. Meta-analysis of 375,000 individuals identifies 38 susceptibility loci for migraine. Nat Genet. 2016;48:856-66.

21. Tsai C, Liang CS, Lin GY, et al. Identifying genetic variants for age of migraine onset in a Han Chinese population in Taiwan. J Headache Pain. 2021;22:89.

22. Kostev K, Bohlken J, Jacob L. Association between migraine headaches and dementia in more than 7,400 patients followed in general practices in the United Kingdom. J Alzheimers Dis. 2019;71:353-60.

23. Hurh K, Jeong SH, Kim SH, Jang SY, Park EC, Jang SI. Increased risk of all-cause, Alzheimer’s, and vascular dementia in adults with migraine in Korea: a population-based cohort study. J Headache Pain. 2022;23:108.

24. Islamoska S, Hansen ÅM, Wang HX, et al. Mid- to late-life migraine diagnoses and risk of dementia: a national register-based follow-up study. J Headache Pain. 2020;21:98.

25. Islamoska S, Hansen JM, Hansen ÅM, Garde AH, Waldemar G, Nabe-Nielsen K. The association between migraine and dementia - a national register-based matched cohort study. Public Health. 2022;213:54-60.

26. Zhu W, Zhan Y, Pei J, et al. Migraine is a risk factor for dementia: a systematic review and meta-analysis of cohort studies. J Headache Pain. 2025;26:136.

27. Kim J, Ha WS, Park SH, Han K, Baek MS. Association between migraine and Alzheimer’s disease: a nationwide cohort study. Front Aging Neurosci. 2023;15:1196185.

28. Lee SY, Lim JS, Oh DJ, Kong IG, Choi HG. Increased risk of neurodegenerative dementia in women with migraines: A nested case-control study using a national sample cohort. Medicine. 2019;98:e14467.

29. Chen Q, Zhang C, Wu S, et al. Genetic evidence for causal association between migraine and dementia: a mendelian randomization study. BMC Med Genomics. 2024;17:180.

30. Kurki MI, Karjalainen J, Palta P, et al. FinnGen provides genetic insights from a well-phenotyped isolated population. Nature. 2023;613:508-18.

31. Bulik-Sullivan B, Finucane HK, Anttila V, et al. An atlas of genetic correlations across human diseases and traits. Nat Genet. 2015;47:1236-41.

32. Zhu Z, Anttila V, Smoller JW, Lee PH. Statistical power and utility of meta-analysis methods for cross-phenotype genome-wide association studies. PLoS One. 2018;13:e0193256.

33. Zhang Y, Xu F, Wang T, et al. Shared genetics and causal association between plasma levels of SARS‐CoV‐2 entry receptor ACE2 and Alzheimer’s disease. CNS Neurosci Ther. 2024;30:e14873.

34. Zerbino DR, Achuthan P, Akanni W, et al. Ensembl 2018. Nucleic Acids Res. 2018;46:D754-61.

35. Lu Y, Quan C, Chen H, Bo X, Zhang C. 3DSNP: a database for linking human noncoding SNPs to their three-dimensional interacting genes. Nucleic Acids Res. 2017;45:D643-9.

36. Giambartolomei C, Vukcevic D, Schadt EE, et al. Bayesian test for colocalisation between pairs of genetic association studies using summary statistics. PLoS Genet. 2014;10:e1004383.

37. Wu X, Xiao C, Han Z, et al. Investigating the shared genetic architecture of uterine leiomyoma and breast cancer: a genome-wide cross-trait analysis. Am J Hum Genet. 2022;109:1272-85.

38. Watanabe K, Taskesen E, van Bochoven A, Posthuma D. Functional mapping and annotation of genetic associations with FUMA. Nat Commun. 2017;8:1826.

39. Zhou Y, Zhou B, Pache L, et al. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat Commun. 2019;10:1523.

40. Wu X, Zhang W, Zhao X, et al. Investigating the relationship between depression and breast cancer: observational and genetic analyses. BMC Med. 2023;21:170.

41. Cannon M, Stevenson J, Stahl K, et al. DGIdb 5.0: rebuilding the drug-gene interaction database for precision medicine and drug discovery platforms. Nucleic Acids Res. 2024;52:D1227-35.

42. Yoo M, Shin J, Kim J, et al. DSigDB: drug signatures database for gene set analysis. Bioinformatics. 2015;31:3069-71.

43. Wang Q, Dhindsa RS, Carss K, et al. ; AstraZeneca Genomics Initiative. Rare variant contribution to human disease in 281,104 UK Biobank exomes. Nature. 2021;597:527-32.

44. Yang J, Wang L, Byrnes JR, et al. PVRL2 suppresses antitumor immunity through PVRIG- and TIGIT-independent pathways. Cancer Immunol Res. 2024;12:575-91.

45. Ortega-Rojas J, Morales L, Guerrero E, et al. Association analysis of polymorphisms in TOMM40, CR1, PVRL2, SORL1, PICALM, and 14q32.13 regions in colombian Alzheimer disease patients. Alzheimer Dis Assoc Disord. 2016;30:305-9.

46. Liu J, Zhao W, Ware EB, Turner ST, Mosley TH, Smith JA. DNA methylation in the APOE genomic region is associated with cognitive function in African Americans. BMC Med Genomics. 2018;11:43.

47. Liang X, Liu C, Liu K, et al. Association and interaction of TOMM40 and PVRL2 with plasma amyloid-β and Alzheimer’s disease among Chinese older adults: a population-based study. Neurobiol Aging. 2022;113:143-51.

48. Chen YC, Chang SC, Lee YS, et al. TOMM40 genetic variants cause neuroinflammation in Alzheimer’s disease. Int J Mol Sci. 2023;24:4085.

49. Muiño E, Carcel-Marquez J, Llucià-Carol L, et al. Identification of genetic loci associated with intracerebral hemorrhage using a multitrait analysis approach. Neurology. 2024;103:e209666.

50. Yu WY, Sun TH, Hsu KC, et al. Comparative analysis of machine learning algorithms for Alzheimer’s disease classification using EEG signals and genetic information. Comput Biol Med. 2024;176:108621.

51. Qiu W, Guo X, Lin X, et al. Transcriptome-wide piRNA profiling in human brains of Alzheimer’s disease. Neurobiol Aging. 2017;57:170-7.

52. Ando K, Nagaraj S, Küçükali F, et al. PICALM and Alzheimer’s disease: an update and perspectives. Cells. 2022;11:3994.

53. Schröder S, Fuchs U, Gisa V, et al. PRDM16-DT is a novel lncRNA that regulates astrocyte function in Alzheimer’s disease. Acta Neuropathol. 2024;148:32.

54. Shigemizu D, Akiyama S, Suganuma M, et al. Classification and deep-learning-based prediction of Alzheimer disease subtypes by using genomic data. Transl Psychiatry. 2023;13:232.

55. Sack A, Samera GJ, Hissen A, et al. A structural analysis of the splice-specific functional impact of the pathogenic familial hemiplegic migraine type 1 S218L mutation on Cav2.1 P/Q-type channel gating. Mol Brain. 2024;17:82.

56. Szymanowicz O, Drużdż A, Słowikowski B, et al. A review of the CACNA gene family: its role in neurological disorders. Diseases. 2024;12:90.

57. Zhang X, Zou M, Wu Y, et al. Regulation of the late onset Alzheimer’s disease associated HLA-DQA1/DRB1 expression. Am J Alzheimers Dis Other Demen. 2022;37:15333175221085066.

58. Owens HA, Thorburn LE, Walsby E, et al. Alzheimer’s disease‐associated P460L variant of EphA1 dysregulates receptor activity and blood‐brain barrier function. Alzheimers Dement. 2024;20:2016-33.

59. Kosoy R, Fullard JF, Zeng B, et al. Genetics of the human microglia regulome refines Alzheimer’s disease risk loci. Nat Genet. 2022;54:1145-54.

60. Watson CN, Belli A, Di Pietro V. Small non-coding RNAs: new class of biomarkers and potential therapeutic targets in neurodegenerative disease. Front Genet. 2019;10:364.

61. Dhillon S. Sutimlimab: first approval. Drugs. 2022;82:817-23.

62. Papatheodorou I, Moreno P, Manning J, et al. Expression Atlas update: from tissues to single cells. Nucleic Acids Res. 2020;48:D77-83.

63. He P, Cao RR, Deng FY, Lei SF. Identification of potential pleiotropic genes for immune and skeletal diseases using multivariate MetaCCA analysis. Curr Genomics. 2021;22:596-606.